Recent Updates
Recently added Catalysts
OKUR Positive Sentiment

OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference

Monday, August 31, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: OnKure Therapeutics, a clinical-stage biopharmaceutical company, has announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference. This event is an opportunity for the company's senior management to engage with investors and discuss their development of novel precision medicines.

Market Sentiment Analysis

POSITIVE FACTORS

  • OnKure Therapeutics is actively engaging with investors.
  • Participation in a prestigious conference highlights company visibility.
  • Focus on novel precision medicines indicates innovation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+127%
120-day peak, hindsight
Typical move
13.8%
average across 2 past catalysts
Cash runway
~50 mo
Minimal dilution risk
Lead asset
OKI-179+ binimetinib
Phase 2 · RAS Mutation

Full Press Release Details

BOULDER, Colo., Aug. 31, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that senior management will participate in the upcoming Morgan Stanley 24th Annual Global

Frequently Asked Questions

What is the purpose of the Morgan Stanley conference?

The conference aims to facilitate engagement between companies and investors.

Who will represent OnKure Therapeutics at the conference?

Senior management from OnKure Therapeutics will participate in the event.

What is OnKure Therapeutics focused on developing?

The company focuses on novel precision medicines.

ShareAdd on Google
Tags: OKUR Viatris Investor Conferences Healthcare OnKure Therapeutics Morgan Stanley Global Healthcare Conference precision medicines
Last updated: Aug 31, 2026

Biotech snapshot

Cash runway
$176M liquidity · $3M/mo burn
~50 mo
Minimal dilution risk
Lead asset
OKI-179+ binimetinibPhase 2
RAS Mutation →

Catalyst track record

+127%
best trade around OKUR's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for OKUR.

See every catalyst's timing & PoA →